ALK-positive anaplastic large cell lymphoma

Summary

ALK-positive anaplastic large cell lymphoma (MONDO:0017602) is a cancer and 20 clinical trials. Top therapeutic interventions include brentuximab vedotin, crizotinib, and brigatinib. A subtype of anaplastic large cell lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: Unknown (Europe)
• Clinical trials: 20

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ALK-positive anaplastic large cell lymphoma
Mondo ID	MONDO:0017602
Orphanet	300895
ICD-10-CM	C84.6
NCIT	C37193
UMLS	C1332079
MedGen	233117
GARD	0021251
Is cancer (heuristic)	yes

Also known as: ALCL, ALK+ · ALK+ ALCL · ALK+ anaplastic large cell lymphoma · ALK-positive anaplastic large cell lymphoma · ALKoma · anaplastic large cell lymphoma, ALK-positive

Data availability: 17 cell lines.

Disease family

This is a subtype of anaplastic large cell lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › T-cell and NK-cell neoplasm › neoplasm of mature T-cells or NK-cells › mature T-cell and NK-cell non-Hodgkin lymphoma › anaplastic large cell lymphoma › ALK-positive anaplastic large cell lymphoma

Related subtypes (4): central nervous system anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, ALK-negative anaplastic large cell lymphoma, small cell variant anaplastic large cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 20.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	8
PHASE1/PHASE2	7
Not specified	3
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03707847	PHASE4	UNKNOWN	Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL
NCT02978625	PHASE2	ACTIVE_NOT_RECRUITING	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT03113500	PHASE2	ACTIVE_NOT_RECRUITING	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT04925609	PHASE1/PHASE2	RECRUITING	Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
NCT07013565	PHASE2	RECRUITING	Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
NCT01979536	PHASE2	COMPLETED	Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
NCT02419287	PHASE2	COMPLETED	Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas
NCT02462538	PHASE1/PHASE2	TERMINATED	Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
NCT02561273	PHASE1/PHASE2	COMPLETED	Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin’s Lymphoma
NCT02729961	PHASE1/PHASE2	WITHDRAWN	Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
NCT03493451	PHASE2	COMPLETED	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03505554	PHASE2	UNKNOWN	A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
NCT03719898	PHASE2	WITHDRAWN	Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
NCT04058470	PHASE1/PHASE2	UNKNOWN	Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
NCT04476459	PHASE1/PHASE2	UNKNOWN	Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
NCT04796857	PHASE1/PHASE2	UNKNOWN	Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
NCT06176690	PHASE1	RECRUITING	Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
NCT05978141	Not specified	RECRUITING	A Registry for People With T-cell Lymphoma
NCT03603847	Not specified	COMPLETED	Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma
NCT05934045	Not specified	UNKNOWN	Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BRENTUXIMAB VEDOTIN	4	4
CRIZOTINIB	4	3
BRIGATINIB	4	2
CERITINIB	4	1
ETOPOSIDE	4	1
ETOPOSIDE PHOSPHATE	4	1
LORLATINIB	4	1
TALIMOGENE LAHERPAREPVEC	4	1
TISLELIZUMAB	4	1
TORIPALIMAB	4	1
VINBLASTINE	4	1
CHEMBL1825138	0	3
CHEMBL1825141	0	3
CHEMBL3397300	0	2
CHEMBL4303155	0	1
CHEMBL4436406	0	1
CHEMBL5289235	0	1
CHEMBL4788494	0	1